Vor Biopharma (VOR) Change in Accured Expenses (2020 - 2026)

Vor Biopharma (VOR) has 7 years of Change in Accured Expenses data on file, last reported at -$9.1 million in Q1 2026.

• On a quarterly basis, Change in Accured Expenses fell 562.78% year-over-year to -$9.1 million in Q1 2026; TTM through Mar 2026 was $3.2 million, a 4.39% decrease from a year earlier, with the FY2025 full-year figure at $10.9 million, up 387.73% from the prior year.
• Change in Accured Expenses for Q1 2026 stood at -$9.1 million, down from $6.2 million in the prior quarter.
• Over the last five years, Change in Accured Expenses for VOR reached as high as $6.2 million in Q4 2025 and fell as low as -$9.1 million in Q1 2026.
• Historically, Change in Accured Expenses has averaged $472647.1 across 5 years, with a median of $485000.0 in 2024.
• Across the five-year window, Change in Accured Expenses jumped 2200.0% in 2022 and tumbled 2720.45% in 2024, its largest moves.
• Year by year, Change in Accured Expenses stood at $1.7 million in 2022, then tumbled by 89.61% to $172000.0 in 2023, then jumped by 2043.6% to $3.7 million in 2024, then soared by 68.32% to $6.2 million in 2025, then sank by 246.63% to -$9.1 million in 2026.
• Per Business Quant data, the three most recent Change in Accured Expenses figures were -$9.1 million in Q1 2026, $6.2 million in Q4 2025, and $5.0 million in Q3 2025.